Phospho-p70S6K and cdc2/cdk1 as therapeutic targets for diffuse large B-cell lymphoma

Expert Opinion on Therapeutic Targets

Volumn 13, Issue 9, 2009, Pages 1085-1093

  Zhao, Xianfeng Frank ^a,b   Gartenhaus, Ronald B ^a,c  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c BALTIMORE VA MEDICAL CENTER   (United States)

Author keywords

cdc2 cdk1; Combination therapy; Diffuse large B cell lymphoma; p70S6K

Indexed keywords

7 HYDROXYSTAUROSPORINE; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 4; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN P21; PROTEIN SERINE THREONINE KINASE; RAPAMYCIN; RITUXIMAB; S6 KINASE; STAUROSPORINE; SURVIVIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; B CELL LYMPHOMA; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE REGULATION; CHROMOSOME 17Q; DRUG RESEARCH; DRUG TARGETING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE LOCATION; GENE OVEREXPRESSION; HUMAN; LARGE CELL LYMPHOMA; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CDC2 PROTEIN KINASE; CYCLIN B; DRUG DELIVERY SYSTEMS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; PHOSPHORYLATION; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA;

EID: 68549135304     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728220903103833     Document Type: Review

References (90)

1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998;16:2780-2795
2. Levitt M, Marsh JC, Deconti RC, et al. Combination sequential chemotherapy in advanced reticulum cell sarcoma. Cancer 1972;29:630-636
3. Elias L, Portlock CS, Rosenberg SA. Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP). Cancer 1978;42:1705-1710 (Pubitemid 9053509)
4. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242 (Pubitemid 34438862)
5. Pfreundschuh M, Trumper L, Gill D, et al. First analysis of the completed Mabthera International (MInT) trial in young patients with low-risk diffuse large B-cell lymphoma (DLBCL): addition of rituximab to a CHOP-like regimen significantly improves outcome of all patients with the identification of a very favorable subgroup with IPI=O and no bulky disease [abstract 157]. Blood 2004;104:48
6. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23:4117-4126 (Pubitemid 46211317)
7. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68-74 (Pubitemid 34101731)
8. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003;102:3871-3879 (Pubitemid 37486965)
9. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappa-B activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;194:1861-1874 (Pubitemid 34028664)
10. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002;14:381-395
11. Hu L, Hofmann J, Lu Y, et al. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 2002;62:1087-1092 (Pubitemid 34160292)
12. Krystal GW, Sulanke G, Litz J. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther 2002;1:913-922
13. Zhao MY, Auerbach A, D'Costa AM, et al. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy. Clin Cancer Res 2009;15:1708-1720
14. Monni O, Barlund M, Mousses S, et al. Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer. Proc Natl Acad Sci USA 2001;98:5711-5716 (Pubitemid 32435707)
15. Grove JR, Banerjee P, Balasubramanyam A, et al. Cloning and expression of two human p70 S6 kinase polypeptides differing only at their amino termini. Mol Cell Biol 1991;11:5541-5550 (Pubitemid 21895320)
16. Reinhard C, Thomas G, Kozma SC. A single gene encodes two isoforms of the p70 S6 kinase: activation upon mitogenic stimulation. Proc Natl Acad Sci USA 1992;89:4052-4056
17. Ferrari S, Thomas G. S6 phosphorylation and the p70s6k/p85s6k. Crit Rev Biochem Mol Biol 1994;29:385-413
18. Burnett PE, Barrow RK, Cohen NA, et al. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci USA 1998;95:1432-1437
19. Saitoh M, Pullen N, Brennan P, et al. Regulation of an activated S6 kinase 1 variant reveals a novel mammalian target of rapamycin phosphorylation site. J Biol Chem 2002;277:20104-20112 (Pubitemid 34967534)
20. Pullen N, Thomas G. The modular phosphorylation and activation of p70s6k. FEBS Lett 1997;410:78-82
21. Weng QP, Kozlowski M, Belham C, et al. Regulation of the p70S6 kinase by phosphorylation in vivo. Analysis using site-specific anti-phosphopeptide antibodies. J Biol Chem 1998;273:16621-16629 (Pubitemid 28311452)
22. Kawasome H, Papst P, Webb S, et al. Targeted disruption of p70(s6k) defines its role in protein synthesis and rapamycin sensitivity. Proc Natl Acad Sci USA 1998;95:5033-5038 (Pubitemid 28208545)
23. Brown RE, Kamal NR. p-p70S6K (Thr389) expression in nodular sclerosing Hodgkin's disease as evidence for receptor tyrosine kinase signaling. Ann Clin Lab Sci 2005;35:413-414
24. Hachem A, Gartenhaus RB. Oncogenes as molecular targets in lymphoma. Blood 2005;106:1911-1923
25. Chung J, Grammer TC, Lemon KP, et al. PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase. Nature 1994;370:71-75 (Pubitemid 24216956)
26. Monfar M, Lemon KP, Grammer TC, et al. Activation of pp70/85 S6 kinases in interleukin-2-responsive lymphoid cells is mediated by phosphatidylinositol 3-kinase and inhibited by cyclic AMP. Mol Cell Biol 1995;15:326-337 (Pubitemid 24379930)
27. Klippel A, Kavanaugh WM, Pot D, Williams LT. A specific product of phosphatidylinositol 3-kinase directly activates the protein kinase Akt through its pleckstrin homology domain. Mol Cell Biol 1997;17:338-344 (Pubitemid 26425623)
28. Burgering BM, Coffer PJ. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 1995;376:599-602
29. Brown EJ, Beal PA, Keith CT, et al. Control of p70S6 kinase by kinase activity of FRAP in vivo. Nature 1995;377:441-446
30. Han JW, Pearson RB, Dennis PB, Thomas G. Rapamycin, wortmannin, and the methylxanthine SQ20006 inactivate p70s6k by inducing dephosphorylation of the same subset of sites. J Biol Chem 1995;270:21396-21403
31. Isotani S, Hara K, Tokunaga C, et al. Immunopurified mammalian target of rapamycin phosphorylates and activates p70 S6 kinase alpha in vitro. J Biol Chem 1999;274:34493-34498 (Pubitemid 129511797)
32. Kim DH, Sarbassov DD, Ali SM, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002;110:163-175
33. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006;22:159-168
34. Chung J, Kuo CJ, Crabtree GR, Blenis J. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell 1992;69:1227-1236
35. Volarevi S, Thomas G. Role of S6 phosphorylation and S6 kinase in cell growth. Prog Nucleic Acid Res Mol Biol 2001;65:101-127
36. Avruch J, Belham C, Weng Q, et al. The p70 S6 kinase integrates nutrient and growth signals to control translational capacity. Prog Mol Subcell Biol 2001;26:115-154
37. Dufner A, Thomas G. Ribosomal S6 kinase signaling and the control of translation. Exp Cell Res 1999;253:100-109
38. Balendran A, Currie R, Armstrong CG, et al. Evidence that 3-phosphoinositide-dependent protein kinase-1 mediates phosphorylation of p70 S6 kinase in vivo at Thr-412 as well as Thr-252. J Biol Chem 1999;274:37400-37406 (Pubitemid 30016825)
39. Alessi DR, Kozlowski MT, Weng QP, et al. 3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro. Curr Biol 1998;8:69-81
40. Pullen N, Dennis PB, Andjelkovic M, et al. Phosphorylation and activation of p70s6k by PDK1. Science 1998;279:707-710
41. Belham C, Comb MJ, Avruch J. Identification of the NIMA family kinases NEK6/7 as regulators of the p70 ribosomal S6 kinase. Curr Biol 2001;11:1155-1167 (Pubitemid 32722568)
42. Romanelli A, Dreisbach VC, Blenis J. Characterization of phosphatidylinositol 3-kinase-dependent phosphorylation of the hydrophobic motif site Thr(389) in p70 S6 kinase 1. J Biol Chem 2002;277:40281-40289
43. Gonzalez-Garcia A, Garrido E, Hernandez C, et al. A new role for the p85-phosphatidylinositol 3-kinase regulatory subunit linking FRAP to p70S6 kinase activation. J Biol Chem 2002;277:1500-1508 (Pubitemid 34968906)
44. Calvo V, Crews CM, Vik TA, Bierer BE. Interleukin 2 stimulation of p70 S6 kinase activity is inhibited by the immunosuppressant rapamycin. Proc Natl Acad Sci USA 1992;89:7571-7575
45. Calvo V, Wood M, Gjertson C, et al. Activation of 70-kDa S6 kinase, induced by the cytokines interleukin-3 and erythropoietin and inhibited by rapamycin, is not an absolute requirement for cell proliferation. Eur J Immunol 1994;24:2664-2671 (Pubitemid 24342181)
46. Reif K, Burgering BM, Cantrell DA. Phosphatidylinositol 3-kinase links the interleukin-2 receptor to protein kinase B and p70 S6 kinase. J Biol Chem 1997;272:14426-14433 (Pubitemid 27232861)
47. Pearson RB, Thomas G. Regulation of p70s6k/p85s6k and its role in the cell cycle. Prog Cell Cycle Res 1995;1:21-32
48. Lane HA, Fernandez A, Lamb NJ, Thomas G. p70s6k function is essential for G1 progression. Nature 1993;363:170-172 (Pubitemid 23147016)
49. Dhar R, Basu A. Constitutive activation of p70 S6 kinase is associated with intrinsic resistance to cisplatin. Int J Oncol 2008;32:1133-1137
50. Kwon HK, Bae GU, Yoon JW, et al. Constitutive activation of p70S6k in cancer cells. Arch Pharm Res 2002;25:685-690 (Pubitemid 43104196)
51. Dutton A, Reynolds GM, Dawson CW, et al. Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR. J Pathol 2005;205:498-506 (Pubitemid 40361339)
52. Rudelius M, Pittaluga S, Nishizuka S, et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 2006;108:1668-1676 (Pubitemid 44316136)
53. Vega F, Medeiros LJ, Leventaki V, et al. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res 2006;66:6589-6597 (Pubitemid 44085614)
54. Leseux L, Hamdi SM, Al Saati T, et al. Syk-dependent mTOR activation in follicular lymphoma cells. Blood 2006;108:4156-4162 (Pubitemid 44913287)
55. Harada H, Andersen JS, Mann M, et al. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci USA 2001;98:9666-9670 (Pubitemid 32769360)
56. Kuo CJ, Chung J, Fiorentino DF, et al. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature 1992;58:70-73
57. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307:1098-1101
58. Decker T, Hipp S, Ringshausen I, et al. Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood 2003;101:278-285 (Pubitemid 36025919)
59. Gaben AM, Saucier C, Bedin M, et al. Rapamycin inhibits cdk4 activation, p 21(WAF1/CIP1) expression and G1-phase progression in transformed mouse fibroblasts. Int J Cancer 2004;108:200-6
60. Jundt F, Raetzel N, Müller C, et al. A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas. Blood 2005;106:1801-1807
61. Wanner K, Hipp S, Oelsner M, et al. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br J Haematol 2006;134:475-484 (Pubitemid 44141713)
62. Lee MG, Nurse P. Complementation used to clone a human homologue of the fission yeast cell cycle control gene cdc2. Nature 1987;327:31-35 (Pubitemid 17063755)
63. Jeffrey PD, Russo AA, Polyak K, et al. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 1995;376:313-320
64. Pines J. Cell cycle. Confirmational change. Nature 1995;376:294-295
65. Stark GR, Taylor WR. Control of the G2/M transition. Mol Biotechnol 2006;32:227-248
66. Jackman M, Firth M, Pines J. Human cyclins B1 and B2 are localized to strikingly different structures: B1 to microtubules, B2 primarily to the Golgi apparatus. EMBO J 1995;14:1646-1654
67. Takizawa CG, Weis K, Morgan DO. Ran-independent nuclear import of cyclin B1-Cdc2 by importin beta. Proc Natl Acad Sci USA 1999;96:7938-7943 (Pubitemid 29328386)
68. Moore JD, Yang J, Truant R, Kornbluth S. Nuclear import of Cdk/cyclin complexes: identification of distinct mechanisms for import of Cdk2/cyclin E and Cdc2/cyclin B1. J Cell Biol 1999;144:213-224 (Pubitemid 29066026)
69. Hagting A, Karlsson C, Clute P, et al. MPF localization is controlled by nuclear export. EMBO J 1998;17:4127-4138 (Pubitemid 28333996)
70. Yang J, Bardes ES, Moore JD, et al. Control of cyclin B1 localization through regulated binding of the nuclear export factor CRM1. Genes Dev 1998;12:2131-2143 (Pubitemid 28348037)
71. Fesquet D, Labbé JC, Derancourt J, et al. The MO15 gene encodes the catalytic subunit of a protein kinase that activates cdc2 and other cyclin-dependent kinases (CDKs) through phosphorylation of Thr161 and its homologues. EMBO J 1993;12:3111-3121 (Pubitemid 23232742)
72. Poon RY, Yamashita K, Adamczewski JP, et al. The cdc2-related protein p40MO15 is the catalytic subunit of a protein kinase that can activate p33cdk2 and p34cdc2. EMBO J 1993;12:3123-3132 (Pubitemid 23232743)
73. Solomon MJ, Harper JW, Shuttleworth J. CAK, the p34cdc2 activating kinase, contains a protein identical or closely related to p40MO15. EMBO J 1993;12:3133-3142 (Pubitemid 23232744)
74. Liu F, Stanton JJ, Wu Z, Piwnica-Worms H. The human Myt1 kinase preferentially phosphorylates Cdc2 on threonine 14 and localizes to the endoplasmic reticulum and Golgi complex. Mol Cell Biol 1997;17:571-583 (Pubitemid 27044356)
75. Parker LL, Piwnica-Worms H. Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science 1992;257:1955-1957
76. Sebastian B, Kakizuka A, Hunter T. Cdc25M2 activation of cyclin-dependent kinases by dephosphorylation of threonine-14 and tyrosine-15. Proc Natl Acad Sci USA 1993;90:3521-3524 (Pubitemid 23111398)
77. Hui D, Reiman T, Hanson J, et al. Immunohistochemical detection of cdc2 is useful in predicting survival in patients with mantle cell lymphoma. Mod Pathol 2005;18:1223-1231 (Pubitemid 43079922)
78. Björck E, Ek S, Landgren O, et al. High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma. Blood 2005;105:2908-2915 (Pubitemid 40446285)
79. Ito Y, Yoshida H, Matsuzuka F, et al. Cdc2 expression in primary thyroid lymphoma: its relationship with biological aggressiveness and G2 cyclins. Pathol Res Pract 2003;199:533-538 (Pubitemid 37193075)
80. Obermann EC, Went P, Pehrs AC, et al. Cyclin B1 expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma. Oncol Rep 2005;14:1461-1467
81. Wang YF, Hsieh YF, Lin CL, et al. Staurosporine-induced G2/M arrest in primary effusion lymphoma BCBL-1 cells. Ann Hematol 2004;83:739-744
82. Goga A, Yang D, Tward AD, et al. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat Med 2007;13:820-827 (Pubitemid 47038193)
83. Faber AC, Chiles TC. Inhibition of cyclin-dependent kinase-2 induces apoptosis in human diffuse large B-cell lymphomas. Cell Cycle 2007;6:2982-2989
84. Ackler S, Xiao Y, Mitten MJ, et al. ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Mol Cancer Ther 2008;7:3265-3274
85. Pei XY, Dai Y, Rahmani M, et al. The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells. Clin Cancer Res 2005;11:4589-4600 (Pubitemid 40825650)
86. West KA, Castillo SS, Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resistance Updat 2002;5:234-248
87. Sato S, Fujita N, Tsuruo T. Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 2002;21:1727-1738 (Pubitemid 34259036)
88. O'Connor DS, Wall NR, Porter AC, Altieri DC. A p34(cdc2) survival checkpoint in cancer. Cancer Cell 2002;2:43-54
89. Figlin RA, Brown E, Armstrong AJ, et al. NCCN Task Force Report: mTOR inhibition in solid tumors. J Natl Compr Canc Netw 2008;6(Suppl 5):S1-20
90. Rizzieri DA, Feldman E, Dipersio JF, et al. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2008;14:2756-2762